Formación Académica y Profesional
Licenciado Matemáticas (Especialidad Fundamentales) por UCM, MBA Executive, MBA Financial Markets, Project Management Excellence Certified
Financial Markets Services Consulting, IT CIO ACO Grupo Santander, IBM Global Services Principal, Electronic Data System Client Ececutive


The mathematician of the Complutense University of Madrid, José-Vidal Ruiz Varela, argues that Europe must raise its borrowing limit, leaving its deflationary policy. Meanwhile, USA must correct debt and raise the interest rates. Raising the interest rates in the USA and dropping them in Europe, recovers the European domestic demand and EE.UU may return to invest in Europe, with a stronger dollar, without any problem, generating hundreds of thousands of Jobs

Curso Superior de #AnálisisDeDatos Contacto :

Curso Superior de #AnálisisDeDatos Contacto :
40 horas. Profesor : José - Vidal Ruiz Varela

Clases Particulares para hacer crecer tu Negocio. #Bigdata #DesarrolloCognitivo

Clases Particulares para hacer crecer tu Negocio. #Bigdata #DesarrolloCognitivo
Profesor : José - Vidal Ruiz Varela

#Bigdata y #Desarrollo #Cognitivo para Personas entre 15 y 65 años

#Bigdata y #Desarrollo #Cognitivo para Personas entre 15 y 65 años
Profesor : José - Vidal Ruiz Varela

Agenda Macro

Agenda de Economía y Finanzas en el Calendario Económico de Español.


Principales Materias Primas

Commodities entregados por

Cotización de las Principales divisas en tiempo real

Cotización de las Principales divisas en tiempo real
e-mail :

Principales Índices Mundiales

El IBEX 35 y los Índices del Mundo son proveídos por Español.

Pfizer profit up on nutrition unit sale gain : Report

Pfizer Inc.'s fourth-quarter earnings soared as the pharmaceutical giant benefited from a gain on the pending sale of its nutrition business and lower acquisition-related charges and other items
For the year, the company projected per-share earnings of $2.20 to $2.30 on revenue of $56.2 billion to $58.2 billion
Analysts polled by Thomson Reuters recently expected $2.29 and $57.56 billion, respectively
Pfizer's animal-medicine business is set to go public on Friday in what would be the largest deal from a U.S. company since Facebook Inc.'s (FB) IPO last May
The animal-health business, which has been dubbed Zoetis Inc., is aiming to raise as much as $2.2 billion in its market debut
The coming IPO is part of Pfizer's plan to shed certain businesses and hone its focus on human pharmaceuticals, partially unwinding years of megamergers that made Pfizer the largest drug maker in the world by sales
Pfizer previously agreed to sell its nutrition unit to Nestle SA  for $11.85 billion in cash
Pfizer reported a profit of $6.32 billion, or 85 cents a share, up from $1.44 billion, or 19 cents a share, a year earlier
The latest period included a per-share contribution of 66 cents from the nutrition business
Excluding restructuring and acquisition-related charges and other items, adjusted earnings from continuing operations were down at 47 cents from 49 cents
Revenue decreased 6.6% to $15.07 billion
Analysts polled by Thomson Reuters most recently projected earnings of 44 cents on revenue of $14.38 billion
U.S. revenue declined 9%, mostly on the loss of exclusivity of Lipitor in November 2011 and Geodon in March 2012
Biopharmaceutical segment sales declined 8.8%, offsetting animal-health sales growth of 5.9% and consumer health-care segment sales improvement of 16%

No hay comentarios: